Using the advantages of small molecule technology platform to establish PDC technology platform to achieve breakthrough and transcendence.

At present, several early projects have been arranged, and 1-2 IND studies are expected to be completed within 2 years.

It relates to powder aerosol, aerosol and inhalation liquid preparation and other high barrier inhalation preparations.

Currently, there are seven inhalation projects under development and two IND studies are expected to be completed this year.

To develop first-in-class, highly selective and effective oral protein-degrading drugs for tumors and autoimmune diseases.

A mature PROTAC platform team has been established, involving chemical synthesis, new drug evaluation, preparation development and quality research, etc., with a total of 85 people, including 13 doctors, master degree or above accounting for more than 60%.

So far, more than 20 early projects have been arranged, and more than 30 patents have been submitted. The most advanced BTK-ProTAC project, HSK29116, has entered phase I clinical practice.